June 23, 2017
Special Issue of Future Medicinal Chemistry Explores Advances in Neurodegenerative Disease Therapy
Future Medicinal Chemistry, a leading MEDLINE indexed journal for medicinal chemists, has published two Special Focus issues on Medicinal Chemistry Advances in Neurodegenerative Disease Therapy.
The World Health Organization estimated that in April 2016 there were 47.5 million people suffering from dementia worldwide and by 2050 this number could triple to a predicted 135.5 million. Despite the efforts of a huge number of research groups around the globe, at present, all neurodegenerative diseases are incurable with only palliative treatments available. Driven by this large and increasing need for new therapies in the field, the journal has come together with renowned experts to deliver this Special Focus issue.
The two Special Focus issues have been guest edited by Maria Laura Bolognesi (University of Bologna, Italy) who provided a scene-setting Foreword in the first issue, and commented, “It seems perfectly logical that we should leave no stone unturned in the fight against neurodegenerative diseases and pursue any drug discovery approach that looks promising. In this context, this special issue, which spans various approaches directed to various neurodegenerative diseases, is very timely and germane to current challenges.”
The Special Focus issues contain a variety of content including editorial, review and research articles looking at the challenges in neurodegenerative disease therapy. The issue covers neurodegeneration as a whole, as well as Alzheimer’s and Parkinson’s disease individually. Topics range from investigating inhibition of amyloid oligomerization to targeting neuroregeneration as a therapeutic strategy.
“I am delighted to have worked with experts from around the globe to produce this timely and comprehensive two-part Special Focus Issue discussing the challenges, advancements and potential therapeutics in neurodegenerative disease,” stated Rachel Coleby, Commissioning Editor of Future Medicinal Chemistry.
To celebrate the release of the Special Focus issues, members of our online community MedChemNet will receive free access to the content from both issues throughout the month of July. Sign up to MedchemNet for free here.
To read Part I of the Special Focus Issue on Advances in Neurodegenerative Disease Therapy, please click here –www.future-science.com/toc/fmc/9/8
To read Part II of the Special Focus Issue on Advances in Neurodegenerative Disease Therapy, please click here –www.future-science.com/toc/fmc/9/10
About Future Medicinal Chemistry
Future Medicinal Chemistry provides monthly commentary and debate on the rapidly evolving field of medicinal chemistry. The MEDLINE-indexed journal showcases milestones in pharmaceutical R&D and features expert analysis of emerging research – from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents. Join the Future Medicinal Chemistry Twitter and Linkedin groups for updates.
Launched in Spring 2015, MedChemNet is among a suite of online networks from Future Science Group focusing on a range of aspects in medicinal and scientific discovery and enterprise. MedChemNet, is free to join and provides a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships. Ultimately, we hope this dynamic network will provide a catalyst to accelerate progress and encourage collaboration in this ever changing field.
Join MedChemNet and help us to connect the dots– https://www.future-science-group.com/joinmcn_nuerodegenerative_disease-therapy/
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. www.futuresciencegroup.com.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.